A new drug to treat advanced skin cancer, or metastatic melanoma, has been shown to nearly double average survival time in a study of more than 130 patients, researchers said Wednesday.
Related posts:
Wounded war veterans find brotherhood in softball
EU OKs Novartis drug Signifor for Cushing's disease
Trial against Big Tobacco starts in Montreal Monday
Skin cancer on the rise among young adults: US study
Rare Diseases: 5 Recent Reasons to Cheer
Taking Anti-HIV Meds Prior to Exposure May Help Prevent Infection
Views: 0